Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Steve Gyorffy"'
Publikováno v:
Journal of Clinical Oncology. 38:e15622-e15622
e15622 Background: Historically, oncology drug development can take years to accomplish the goal of bringing new agents to patients. Scientific knowledge is evolving rapidly, transforming our understanding of the diseases at a rapid pace. This necess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0daf3090c08696d9af0a8130c2e053dd
https://doi.org/10.1200/jco.2020.38.15_suppl.e15622
https://doi.org/10.1200/jco.2020.38.15_suppl.e15622
Publikováno v:
Journal of Clinical Oncology. 38:e15632-e15632
e15632 Background: STING activating cyclic-di-nucleotides result in the production of interferons, activating immune cells. We show that “Precision Medicine Knowledge Frames” (PMKF) are analyses inherently involving 2 processes: Frame 1 – Bench
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4297fe05ab199c1f9d572a8739619f86
https://doi.org/10.1200/jco.2020.38.15_suppl.e15632
https://doi.org/10.1200/jco.2020.38.15_suppl.e15632
Publikováno v:
Animal Health Research Reviews. 5:227-234
This review examines the mechanisms involved in anti-tumor immunity and how peptides present in many tumor types (tumor-associated antigens) are recognized by T cells from tumor-bearing cancer patients. Tumor-associated antigens are derived from prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab2f814f4baaff822ea791793a07e32d
https://doi.org/10.1079/ahr200473
https://doi.org/10.1079/ahr200473
Publikováno v:
The American Journal of Pathology. 161:909-918
Endometriosis, the growth of ectopic endometrial tissue, is a chronic recurrent disease affecting 10% of the female population causing dyspareunia, pelvic pain, dysmenorrhea, and infertility. Suppression of ovarian activity is the cornerstone of medi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::614baf9d0e39bc7eeeb5f9b84a84918c
https://doi.org/10.1016/s0002-9440(10)64251-4
https://doi.org/10.1016/s0002-9440(10)64251-4
Autor:
Jack Gauldie, Catherine M. Hoff, Peter J. Margetts, Clifford J. Holmes, Steve Gyorffy, Martin Kolb, Lisa Yu
Publikováno v:
Journal of the American Society of Nephrology. 13:721-728
To identify the relative importance of peritoneal fibrosis and angiogenesis in peritoneal membrane dysfunction, adenoviral mediated gene transfer of angiostatin, a recognized angiogenesis inhibitor, and decorin, a transforming growth factor-beta-inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0370120937c2b322eddcc53e86992e0
https://doi.org/10.1681/asn.v133721
https://doi.org/10.1681/asn.v133721
Autor:
Birgit Gaschler-Markefski, Gerd Munzert, Scott A. Laurie, Holger Fritsch, Peter M. Ellis, Quincy Chu, Natasha B. Leighl, Steve Gyorffy
Publikováno v:
Clinical lung cancer. 14(1)
Introduction BI 2536 is a potent, highly selective inhibitor of polo-like kinase (Plk) 1. This open-label, phase I study investigated the maximum tolerated dose (MTD), safety, efficacy, and pharmacokinetics (PK) of BI 2536 IV in combination with stan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::067a671a7d2ab45da064e6fac7fb6c13
https://pubmed.ncbi.nlm.nih.gov/22658814
https://pubmed.ncbi.nlm.nih.gov/22658814
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 16(10)
Introduction: BIBF 1120 (planned brand name Vargatef) is a novel, oral, triple angiokinase inhibitor targeting three receptor classes involved in blood vessel formation. The objectives of this phase I, open-label dose-escalation study were to determi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bf5c08cd6cf75993c8bdb68414374c5
https://pubmed.ncbi.nlm.nih.gov/20460487
https://pubmed.ncbi.nlm.nih.gov/20460487
Publikováno v:
Contemporary Cancer Research ISBN: 9781588292131
It has been well established that tumor growth depends on angiogenesis, the process of continued expansion of endothelial cells from preexisting blood vessels (1,2). Tumors in situ, which are smaller than 3 mm in diameter, exist in a prevascular stat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::feb45e864cfc90aecf7ba5fbd38c7351
https://doi.org/10.1007/978-1-59259-785-7_17
https://doi.org/10.1007/978-1-59259-785-7_17
Autor:
Steve Gyorffy, Anthony Atala, Jasmin Fuhr, Ying Yu, Joyce Bischoff, John B. Mulliken, Shay Soker, Eileen Boye
Publikováno v:
Stem cells (Dayton, Ohio). 24(6)
Hemangioma is a benign tumor of infancy whose hallmark is rapid growth during the first year of life followed by slow regression during early childhood. The proliferating phase is characterized by abundant immature endothelial cells, the involuting p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0ce06365416e407bf93e1486f347c14
https://pubmed.ncbi.nlm.nih.gov/16456130
https://pubmed.ncbi.nlm.nih.gov/16456130
Publikováno v:
The American journal of pathology. 159(3)
Angiostatin, an internal fragment of plasminogen, has been shown to inhibit the process of angiogenesis or neovascularization. In this study, we have expressed the cDNA for murine angiostatin under the control of the human cytomegalovirus promoter fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0ce7cbe3b4ca465bf6d8ed4d6f4a320
https://pubmed.ncbi.nlm.nih.gov/11549607
https://pubmed.ncbi.nlm.nih.gov/11549607